Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Regression of Diagnostic Data

Arthritis Care and Research

Volumn 70, Issue 3, 2018, Pages 428-438

  Leuchten, Nicolai ^a   Hoyer, Annika ^b   Brinks, Ralph ^c   Schoels, Monika ^d   Schneider, Matthias ^e   Smolen, Josef ^f   Johnson, Sindhu R ^g   Daikh, David ^h   Dörner, Thomas ⁱ   Aringer, Martin ^a   Bertsias, George ^j  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^c Institute for Rheumatology   (Germany)

^d Hietzing Hospital   (Austria)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g UNIVERSITY OF TORONTO   (Canada)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j UNIVERSITY OF CRETE   (Greece)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; BIOLOGICAL MARKER;

ANTIBODY TITER; ARTICLE; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; HEP-2 CELL LINE; HUMAN; IMMUNOFLUORESCENCE TEST; MEASUREMENT ACCURACY; PEDIATRICS; PUBLICATION; RHEUMATOLOGY; SENSITIVITY AND SPECIFICITY; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; CLASSIFICATION; IMMUNOLOGY; META ANALYSIS; PREDICTIVE VALUE; PROGNOSIS; REPRODUCIBILITY; SEROLOGY;

ANTIBODIES, ANTINUCLEAR; BIOMARKERS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SEROLOGIC TESTS;

EID: 85041234022     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.23292     Document Type: Article

References (101)

1. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
2. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–7.
3. Aggarwal R, Ringold S, Khanna D, Neogi T, Johnson SR, Miller A, et al. Distinctions between diagnostic and classification criteria? Arthritis Care Res (Hoboken) 2015;67:891–7.
4. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677–86.
5. Sag E, Tartaglione A, Batu ED, Ravelli A, Khalil SM, Marks SD, et al. Performance of the new SLICC classification criteria in childhood systemic lupus erythematosus: a multicentre study. Clin Exp Rheumatol 2014;32:440–4.
6. Fonseca AR, Gaspar-Elsas MI, Land MG, de Oliveira SK. Comparison between three systems of classification criteria in juvenile systemic lupus erythematous. Rheumatology (Oxford) 2015;54:241–7.
7. Ighe A, Dahlstrom O, Skogh T, Sjowall C. Application of the 2012 Systemic Lupus International Collaborating Clinics classification criteria to patients in a regional Swedish systemic lupus erythematosus register. Arthritis Res Ther 2015;17:3.
8. Ines L, Silva C, Galindo M, Lopez-Longo FJ, Terroso G, Romao VC, et al. Classification of systemic lupus erythematosus: Systemic Lupus International Collaborating Clinics versus American College of Rheumatology criteria. A comparative study of 2,055 patients from a real-life, international systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken) 2015;67:1180–5.
9. Aringer M, Dorner T, Leuchten N, Johnson SR. Toward new criteria for systemic lupus erythematosus: a standpoint. Lupus 2016;25:805–11.
10. Slater CA, Davis RB, Shmerling RH. Antinuclear antibody testing: a study of clinical utility. Arch Int Med 1996;156:1421–5.
11. Eriksson C, Kokkonen H, Johansson M, Hallmans G, Wadell G, Rantapaa-Dahlqvist S. Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden. Arthritis Res Ther 2011;13:R30.
12. Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, et al. Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum 1997;40:1601–11.
13. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526–33.
14. Dasgupta B, Cimmino MA, Maradit Kremers H, Schmidt WA, Schirmer M, Salvarani C, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology Collaborative Initiative. Arthritis Rheum 2012;64:943–54.
15. Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol 2015;67:2557–68.
16. Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 2014;73:17–23.
17. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
18. Derksen RH, Bast EJ, Strooisma T, Jacobs JW. A comparison between the Farr radioimmunoassay and a new automated fluorescence immunoassay for the detection of antibodies against double stranded DNA in serum. Ann Rheum Dis 2002;61:1099–102.
19. Hawro T, Bogucki A, Krupinska-Kun M, Maurer M, Wozniacka A. Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-beta2GPI antibodies in patients with systemic lupus erythematosus. PloS One 2015;10:e0119911.
20. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529–36.
21. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005;58:982–90.
22. Chu H, Cole SR. Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach [letter]. J Clin Epidemiol 2006;59:1331–2.
23. Zou GY, Donner A. Construction of confidence limits about effect measures: a general approach. Stat Med 2008;27:1693–702.
24. Abdwani R, Al-Abrawi S, Sharef SW, Al-Zakwani I. Geographical clustering of juvenile onset systemic lupus erythematosus within the Sultanate of Oman. Oman Med J 2013;28:199–203.
25. Aikawa NE, Jesus AA, Liphaus BL, Silva CA, Carneiro-Sampaio M, Viana VS, et al. Organ-specific autoantibodies and autoimmune diseases in juvenile systemic lupus erythematosus and juvenile dermatomyositis patients. Clin Exp Rheumatol 2012;30:126–31.
26. Alarcon GS, Friedman AW, Straaton KV, Moulds JM, Lisse J, Bastian HM, et al. Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. LUpus in MInority populations: NAture vs. Nurture. Lupus 1999;8:197–209.
27. Al-Jabri AA, Al-Gahdani AK, Al-Shuaili I. High frequency of Smith autoantibodies in Omani patients with systemic lupus erythematosus. Rheumatol Int 2009;30:51–6.
28. Alonso MD, Martinez-Vazquez F, Riancho-Zarrabeitia L, Diaz de Teran T, Miranda-Filloy JA, Blanco R, et al. Sex differences in patients with systemic lupus erythematosus from Northwest Spain. Rheumatol Int 2014;34:11–24.
29. Amezcua-Guerra LM, Higuera-Ortiz V, Arteaga-Garcia U, Gallegos-Nava S, Hubbe-Tena C. Performance of the 2012 Systemic Lupus International Collaborating Clinics and the 1997 American College of Rheumatology classification criteria for systemic lupus erythematosus in a real-life scenario. Arthritis Care Res (Hoboken) 2015;67:437–41.
30. Anaya JM, Uribe M, Perez A, Sanchez JF, Pinto LF, Molina JF, et al. Clinical and immunological factors associated with lupus nephritis in patients from northwestern Colombia. Biomedica 2003;23:293–300.
31. Beutner EH, Blaszczyk M, Jablonska S, Chorzelski TP, Kumar V, Wolska H. Studies on criteria of the European Academy of Dermatology and Venerology for the classification of cutaneous lupus erythematosus: I. Selection of clinical groups and study factors. Int J Dermatol 1991;30:411–7.
32. Bonilla E, Francis L, Allam F, Ogrinc M, Neupane H, Phillips PE, et al. Immunofluorescence microscopy is superior to fluorescent beads for detection of antinuclear antibody reactivity in systemic lupus erythematosus patients. Clin Immunol 2007;124:18–21.
33. Borba EF, Araujo DB, Bonfa E, Shinjo SK. Clinical and immunological features of 888 Brazilian systemic lupus patients from a monocentric cohort: comparison with other populations. Lupus 2013;22:744–9.
34. Braun A, Sis J, Max R, Mueller K, Fiehn C, Zeier M, et al. Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases. Scand J Rheumatol 2007;36:291–8.
35. Bruner BF, Guthridge JM, Lu R, Vidal G, Kelly JA, Robertson JM, et al. Comparison of autoantibody specificities between traditional and bead-based assays in a large, diverse collection of patients with systemic lupus erythematosus and family members. Arthritis Rheum 2012;64:3677–86.
36. Caccavo D, Rigon A, Picardi A, Galluzzo S, Vadacca M, Ferri GM, et al. Anti-lactoferrin antibodies in systemic lupus erythematosus: isotypes and clinical correlates. Clin Rheumatol 2005;24:381–7.
37. Cefle A, Inanc M, Sayarlioglu M, Kamali S, Gul A, Ocal L, et al. Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphospholipid antibodies and severe disease outcome. Rheumatol Int 2011;31:183–9.
38. Christian N, Smikle MF, DeCeulaer K, Daniels L, Walravens MJ, Barton EN. Antinuclear antibodies and HLA class II alleles in Jamaican patients with systemic lupus erythematosus. West Indian Med J 2007;56:130–3.
39. Clegg DO, Williams HJ, Singer JZ, Steen VD, Schlegel S, Ziminski C, et al. Early undifferentiated connective tissue disease: II. The frequency of circulating antinuclear antibodies in patients with early rheumatic diseases. J Rheumatol 1991;18:1340–3.
40. Cooper GS, Parks CG, Treadwell EL, St.Clair EW, Gilkeson GS, Cohen PL, et al. Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States. Lupus 2002;11:161–7.
41. Copple SS, Martins TB, Masterson C, Joly E, Hill HR. Comparison of three multiplex immunoassays for detection of antibodies to extractable nuclear antibodies using clinically defined sera. Ann N Y Acad Sci 2007;1109:464–72.
42. Dipti TR, Azam MS, Sattar MH, Rahman SA. Detection of anti-nuclear antibody by immunofluorescence assay and enzyme immunoassay in childhood systemic lupus erythematosus: experience from Bangladesh. Int J Rheum Dis 2012;15:121–5.
43. Edworthy S, Fritzler M, Whitehead C, Martin L, Rattner JB. ASE-1: an autoantigen in systemic lupus erythematosus. Lupus 2000;9:681–7.
44. El-Chennawi FA, Mosaad YM, Habib HM, El-Degheidi T. Comparative study of antinuclear antibody detection by indirect immunofluorescence and enzyme immunoassay in lupus patients. Immunol Invest 2009;38:839–50.
45. Emlen W, O'Neill L. Clinical significance of antinuclear antibodies: comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays. Arthritis Rheum 1997;40:1612–8.
46. Farid EM, Hassan AB, Abalkhail AA, El-Agroudy AE, Arrayed SA, Al-Ghareeb SM. Immunological aspects of biopsy-proven lupus nephritis in Bahraini patients with systemic lupus erythematosus. Saudi J Kidn Dis Trans 2013;24:1271–9.
47. Fawcett PT, Rose CD, Gibney KM, Emerich MJ, Athreya BH, Doughty RA. Use of ELISA to measure antinuclear antibodies in children with juvenile rheumatoid arthritis. J Rheumatol 1999;26:1822–6.
48. Fredi M, Cavazzana I, Quinzanini M, Taraborelli M, Cartella S, Tincani A, et al. Rare autoantibodies to cellular antigens in systemic lupus erythematosus. Lupus 2014;23:672–7.
49. Gerli R, Caponi L, Tincani A, Scorza R, Sabbadini MG, Danieli MG, et al. Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatology (Oxford) 2002;41:1357–66.
50. Ghosh P, Dwivedi S, Naik S, Agarwal V, Verma A, Aggarwal A, et al. Antinuclear antibodies by indirect immunofluorescence: optimum screening dilution for diagnosis of systemic lupus erythematosus. Indian J Med Res 2007;126:34–8.
51. Gokce M, Bilginer Y, Besbas N, Ozaltin F, Cetin M, Gumruk F, et al. Hematological features of pediatric systemic lupus erythematosus: suggesting management strategies in children. Lupus 2012;21:878–84.
52. Govoni M, Bombardieri S, Bortoluzzi A, Caniatti L, Casu C, Conti F, et al. Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. Rheumatology (Oxford) 2012;51:157–68.
53. Haddouk S, Marzouk S, Jallouli M, Fourati H, Frigui M, Hmida YB, et al. Clinical and diagnostic value of ribosomal P autoantibodies in systemic lupus erythematosus. Rheumatology (Oxford) 2009;48:953–7.
54. Hanly JG, Thompson K, McCurdy G, Fougere L, Theriault C, Wilton K. Measurement of autoantibodies using multiplex methodology in patients with systemic lupus erythematosus. J Immunol Meth 2010;352:147–52.
55. Hayashi N, Kawamoto T, Mukai M, Morinobu A, Koshiba M, Kondo S, et al. Detection of antinuclear antibodies by use of an enzyme immunoassay with nuclear HEp-2 cell extract and recombinant antigens: comparison with immunofluorescence assay in 307 patients. Clin Chem 2001;47:1649–59.
56. Jaekell HP, Trabandt A, Grobe N, Werle E. Anti-dsDNA antibody subtypes and anti-C1q antibodies: toward a more reliable diagnosis and monitoring of systemic lupus erythematosus and lupus nephritis. Lupus 2006;15:335–45.
57. Jeon YL, Kim MH, Lee WI, Kang SY. Comparison of indirect immunofluorescence and line immunoassay for autoantibody detection. Clin Exp Rheumatol 2013;31:84–90.
58. Julkunen H, Salonen EM, Walle TK, Miettinen A. Anti-nucleosome antibodies in the diagnosis of systemic lupus erythematosus. Scand J Rheumatol 2005;34:122–4.
59. Kamen DL, Barron M, Parker TM, Shaftman SR, Bruner GR, Aberle T, et al. Autoantibody prevalence and lupus characteristics in a unique African American population. Arthritis Rheum 2008;58:1237–47.
60. Keusseyan SP, da Silva NP, Hilario MO, Okuda EM, Terreri MT, Andrade LE. Diagnostic performance and clinical associations of antibodies to the chromatin antigenic system in juvenile systemic lupus erythematosus. Rev Bras Reumatol 2012;52:695–712.
61. Lee SS, Li CS, Li PC. Clinical profile of Chinese patients with systemic lupus erythematosus. Lupus 1993;2:105–9.
62. Li J, Leng X, Li Z, Ye Z, Li C, Li X, et al. Chinese SLE treatment and research group registry: III. association of autoantibodies with clinical manifestations in Chinese patients with systemic lupus erythematosus [abstract]. J Immunol Res 2014;2014:809389.
63. Mariz HA, Sato EI, Barbosa SH, Rodrigues SH, Dellavance A, Andrade LE. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody–positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum 2011;63:191–200.
64. Molina JF, Molina J, Garcia C, Gharavi AE, Wilson WA, Espinoza LR. Ethnic differences in the clinical expression of systemic lupus erythematosus: a comparative study between African-Americans and Latin Americans. Lupus 1997;6:63–7.
65. Montecucco C, Caporali R, Ravelli A, Ronchetti A, Rossi S, Martini A, et al. Frequency and clinical significance of anti-RNP antibodies in Italian SLE patients. Ann Ital Med Int 1994;9:12–5.
66. Navarra SV, Ishimori MI, Uy EA, Hamijoyo L, Sama J, James JA, et al. Studies of Filipino patients with systemic lupus erythematosus: autoantibody profile of first-degree relatives. Lupus 2011;20:537–43.
67. Paz E, Adawi M, Lavi I, Mussel Y, Mader R. Antinuclear antibodies measured by enzyme immunoassay in patients with systemic lupus erythematosus: relation to disease activity. Rheum Int 2007;27:941–5.
68. Pluchinotta FR, Schiavo B, Vittadello F, Martini G, Perilongo G, Zulian F. Distinctive clinical features of pediatric systemic lupus erythematosus in three different age classes. Lupus 2007;16:550–5.
69. Quintana G, Coral-Alvarado P, Aroca G, Patarroyo PM, Chalem P, Iglesias-Gamarra A, et al. Single anti-P ribosomal antibodies are not associated with lupus nephritis in patients suffering from active systemic lupus erythematosus. Autoimmun Rev 2010;9:750–5.
70. Ramos PS, Kelly JA, Gray-McGuire C, Bruner GR, Leiran AN, Meyer CM, et al. Familial aggregation and linkage analysis of autoantibody traits in pedigrees multiplex for systemic lupus erythematosus. Gene Immun 2006;7:417–32.
71. Saisoong S, Eiam-Ong S, Hanvivatvong O. Correlations between antinucleosome antibodies and anti-double-stranded DNA antibodies, C3, C4, and clinical activity in lupus patients. Clin Exp Rheumatol 2006;24:51–8.
72. Sarbu MI, Salman-Monte TC, Rubio Munoz P, Lisbona MP, Almirall Bernabe M, Carbonell J. Differences between clinical and laboratory findings in patients with recent diagnosis of SLE according to the positivity of anti-dsDNA by the Crithidia luciliae method. Lupus 2015;24:1198–203.
73. Sardeto GA, Simas LM, Skare TS, Nisihara RM, Utiyama SR. Antinucleosome in systemic lupus erythematosus: a study in a Brazilian population. Clin Rheumatol 2012;31:553–6.
74. Sebastiani GD, Passiu G, Galeazzi M, Porzio F, Carcassi U. Prevalence and clinical associations of anticardiolipin antibodies in systemic lupus erythematosus: a prospective study. Clin Rheumatol 1991;10:289–93.
75. Servais G, Karmali R, Guillaume MP, Badot V, Duchateau J, Corazza F. Anti DNA antibodies are not restricted to a specific pattern of fluorescence on HEp2 cells. Clin Chem Lab Med 2009;47:543–9.
76. Sjowall C, Sturm M, Dahle C, Bengtsson AA, Jonsen A, Sturfelt G, et al. Abnormal antinuclear antibody titers are less common than generally assumed in established cases of systemic lupus erythematosus. J Rheumatol 2008;35:1994–2000.
77. Sparchez M, Delean D, Samasca G, Miu N, Sparchez Z. Antinuclear antibody screening by ELISA and IF techniques: discrepant results in juvenile idiopathic arthritis but consistency in childhood systemic lupus erythematous. Clin Rheumatol 2014;33:643–7.
78. Tarr T, Derfalvi B, Gyori N, Szanto A, Siminszky Z, Malik A, et al. Similarities and differences between pediatric and adult patients with systemic lupus erythematosus. Lupus 2015;24:796–803.
79. Thompson D, Juby A, Davis P. The clinical significance of autoantibody profiles in patients with systemic lupus erythematosus. Lupus 1993;2:15–9.
80. Tikly M, Burgin S, Mohanlal P, Bellingan A, George J. Autoantibodies in black South Africans with systemic lupus erythematosus: spectrum and clinical associations. Clin Rheumatol 1996;15:143–7.
81. Tucker LB, Menon S, Schaller JG, Isenberg DA. Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. Brit J Rheumatol 1995;34:866–72.
82. Ulvestad E. Modelling autoimmune rheumatic disease: a likelihood rationale. Scan J Immunol 2003;58:106–11.
83. Vlachoyiannopoulos PG, Karassa FB, Karakostas KX, Drosos AA, Moutsopoulos HM. Systemic lupus erythematosus in Greece. Clinical features, evolution and outcome: a descriptive analysis of 292 patients. Lupus 1993;2:303–12.
84. Wichainun R, Kasitanon N, Wangkaew S, Hongsongkiat S, Sukitawut W, Louthrenoo W. Sensitivity and specificity of ANA and anti-dsDNA in the diagnosis of systemic lupus erythematosus: a comparison using control sera obtained from healthy individuals and patients with multiple medical problems. Asian Pac J Allergy Immunol 2013;31:292–8.
85. Zimmermann AF, de Messias IJ, Utiyama SR, Chiu YY, Nisihara RM, Moura ML, et al. Clinical, autoimmune and demographic profile in systemic lupus erythematosus (SLE) patients from southern Brazil. J Investig Allergol Clin Immunol 1997;7:24–31.
86. Wells PS, Hirsh J, Anderson DR, Lensing AW, Foster G, Kearon C, et al. Accuracy of clinical assessment of deep-vein thrombosis. Lancet 1995;345:1326–30.
87. McHardy KC, Horne CH, Rennie J. Antinuclear antibody-negative systemic lupus erythematosus: How common? J Clin Pathol 1982;35:1118–21.
88. Cross LS, Aslam A, Misbah SA. Antinuclear antibody-negative lupus as a distinct diagnostic entity: does it no longer exist? QJM 2004;97:303–8.
89. Pourmand N, Blomberg S, Ronnblom L, Karlsson-Parra A, Pettersson I, Wahren-Herlenius M. Ro 52kD autoantibodies are detected in a subset of ANA-negative sera. Scand J Rheumatol 2000;29:116–23.
90. Kidd K, Cusi K, Mueller R, Goodner M, Boyes B, Hoy E. Detection and identification of significant ANAs in previously determined ANA negative samples. Clin Lab 2005;51:517–21.
91. Bizzaro N, Tozzoli R, Tonutti E, Piazza A, Manoni F, Ghirardello A, et al. Variability between methods to determine ANA, anti-dsDNA and anti-ENA autoantibodies: a collaborative study with the biomedical industry. J Immunol Meth 1998;219:99–107.
92. Pham BN, Albarede S, Guyard A, Burg E, Maisonneuve P. Impact of external quality assessment on antinuclear antibody detection performance. Lupus 2005;14:113–9.
93. Koarada S, Ide M, Haruta Y, Tada Y, Ushiyama O, Morito F, et al. Two cases of antinuclear antibody negative lupus showing increased proportion of B cells lacking RP105. J Rheumatol 2005;32:562–4.
94. Kim HA, Chung JW, Park HJ, Joe DY, Yim HE, Park HS, et al. An antinuclear antibody-negative patient with lupus nephritis. Korean J Int Med 2009;24:76–9.
95. Hoyer BF, Schmajuk G, Aringer M, Johnson SR, Daikh DI, Dorner T. Multi-center Delphi exercise reveals important key items in classifying SLE [abstract]. Arthritis Rheum 2015;11:746.
96. Meroni PL, Schur PH. ANA screening: an old test with new recommendations. Ann Rheum Dis 2010;69:1420–2.
97. Egner W. The use of laboratory tests in the diagnosis of SLE. J Clin Pathol 2000;53:424–32.
98. Nilsson BO, Skogh T, Ernerudh J, Johansson B, Lofgren S, Wikby A, et al. Antinuclear antibodies in the oldest-old women and men. J Autoimmun 2006;27:281–8.
99. Mahler M, Parker T, Peebles CL, Andrade LE, Swart A, Carbone Y, et al. Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J Rheumatol 2012;39:2104–10.
100. Bentow C, Fritzler MJ, Mummert E, Mahler M. Recognition of the dense fine speckled (DFS) pattern remains challenging: results from an international internet-based survey. Auto Immun Highlights 2016;7:8.
101. Livingston B, Bonner A, Pope J. Differences in autoantibody profiles and disease activity and damage scores between childhood- and adult-onset systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum 2012;42:271–80.